Minnerop Martina, Herbst Martin, Fimmers Rolf, Kaabar Pavlina, Matz Bertfried, Klockgether Thomas, Wüllner Ullrich
Dept. of Neurology, University Hospital of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
J Neurol. 2008 Nov;255(11):1726-30. doi: 10.1007/s00415-008-0008-6. Epub 2008 Sep 3.
There is insufficient evidence concerning the efficacy of antiviral treatment of Bell's palsy (BP). We therefore compared the efficacy of prednisone and famciclovir to prednisone treatment alone in BP. A total of 167 consecutive patients with untreated acute BP were included. Severity of BP was evaluated using the House-Brackmann scale (HBS) and virus antibody tests (herpes simplex virus, varicella zoster virus) were performed. Patients admitted on even dates were treated with prednisone ("P group") and patients admitted on odd dates were treated with prednisone and famciclovir ("P+F group"). 117 patients completed the follow-up after 3 months or later (67 P/51 P+F). While most patients showed at least partial recovery with both treatment types, improvement of at least 4 grades in the HBS was more common in the "P+F group" (29.4 % vs. 11.9 %), whereas smaller changes of less than 3 grades were more common in the "P group" (29.9 % vs. 17.6 %; Chi-square test, p = 0.02). Patients with complete BP (HBS grade of 5 or 6) had significantly better chances of reaching normal function if treated with famciclovir additionally instead with prednisone alone (73.7 % vs. 47.1 %; Cochran-Armitage trend test, p = 0.03). These results suggest that the combined treatment of famciclovir and prednisolone should be considered (at least) in patients with severe BP.
关于贝尔氏面瘫(BP)抗病毒治疗的疗效,目前证据不足。因此,我们比较了泼尼松联合泛昔洛韦与单独使用泼尼松治疗BP的疗效。共纳入167例未经治疗的急性BP连续患者。使用House-Brackmann量表(HBS)评估BP严重程度,并进行病毒抗体检测(单纯疱疹病毒、水痘带状疱疹病毒)。偶数日入院的患者接受泼尼松治疗(“P组”),奇数日入院的患者接受泼尼松和泛昔洛韦治疗(“P+F组”)。117例患者在3个月或更晚完成随访(67例P组/51例P+F组)。虽然两种治疗方式下大多数患者至少有部分恢复,但HBS至少改善4级在“P+F组”更为常见(29.4%对11.9%),而小于3级的较小变化在“P组”更为常见(29.9%对17.6%;卡方检验,p = 0.02)。完全性BP(HBS分级为5或6级)的患者,如果额外接受泛昔洛韦治疗而非单独使用泼尼松,达到正常功能的机会显著更高(73.7%对47.1%; Cochr an-Armitage趋势检验,p = 0.03)。这些结果表明,(至少)对于重度BP患者应考虑联合使用泛昔洛韦和泼尼松龙进行治疗。